Drug intelligence / Profile preview

TQB3811

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3811 is a second-generation, selective tropomyosin receptor kinase (TRK) inhibitor developed by Chia Tai-Tianqing Pharmaceutical Group. It is designed to inhibit the kinase activity of TRKA, TRKB, and TRKC, including variants with secondary drug-resistant mutations that often arise after treatment with first-generation TRK inhibitors. The drug is currently being evaluated in Phase I clinical trials for the treatment of advanced malignant tumors, particularly those harboring NTRK gene fusions or resistance mutations.

Targets

NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on TQB3811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3811.

Explore the full profile